Cumberland Pharmaceuticals Reports First Quarter 2012 Financial Results
May 3, 2012
|
|
|
 |
|
NASHVILLE, Tenn., May 3, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced first quarter 2012 financial results.
Net Revenues: For the three months ended March 31, 2012, net revenues were $10.3 million, compared...
|
|
Cumberland Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 3, 2012
Apr 12, 2012
|
|
|
|
|
NASHVILLE, Tenn., April 12, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release its first quarter 2012 results after the market closes on Thursday, May 3, 2012. A conference call and live Internet webcast will be held on Thursday, May 3, 2012, at 5:00 p.m. Eastern Time to discuss the results.
...
|
|
Cumberland Pharmaceuticals to Present at Needham Life Sciences Conference in New York on April 3, 2012
Mar 27, 2012
|
|
|
|
|
NASHVILLE, Tenn., March 27, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that Chief Executive Officer A.J. Kazimi will present at the Needham Life Sciences Conference in New York at 2:00 p.m. Eastern Time on Tuesda...
|
|
Cumberland Pharmaceuticals Reports 2011 Annual Financial Results
Feb 29, 2012
|
|
|
|
|
NASHVILLE, Tenn., Feb. 29, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced 2011 annual financial results.
Net Revenue: For the year ended December 31, 2011, net revenue increased to $51.1 million, up 11.5% compared with $...
|
|
Cumberland Pharmaceuticals Signs Exclusive Licensing Agreement for China
Feb 28, 2012
|
|
|
|
|
NASHVILLE, Tenn., Feb. 28, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced it has entered into an exclusive agreement with China's Harbin Gloria Pharmaceuticals Co., Ltd. (SHE: 002437)for the commercialization of Acetadote® (acetylcysteine), its injectable drug used to treat acetaminophen overdose, and Caldo...
|
|
Cumberland Receives Acetadote® Patent Notice of Allowance
Feb 8, 2012
|
|
|
|
|
NASHVILLE, Tenn., Feb. 8, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office relating to its new formulation of Acetadote® (acetylcysteine) Injection, which is used to treat acetaminophen poisoning. The new formulation...
|
|
Cumberland Pharmaceuticals to Announce 2011 Year End Financial Results on February 29, 2012
Feb 8, 2012
|
|
|
|
|
NASHVILLE, Tenn., Feb. 8, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release 2011 year-end financial results after the market closes on Wednesday, February 29, 2012. A conference call and live Internet webcast will be held on Wednesday, February 29, 2012, at 5:00 p.m. Eastern Time to discuss th...
|
|
Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
Nov 3, 2011
|
|
|
|
|
NASHVILLE, Tenn., Nov. 3, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced third quarter 2011 financial results.
Net Revenue: For the three months ended September 30, 2011, net revenue was $13.1 million, up from $1...
|
|
|
|
